New hope for tough blood cancers: experimental drug BL-M08D1 enters human testing
NCT ID NCT06718634
First seen Jan 22, 2026 · Last updated May 12, 2026 · Updated 16 times
Summary
This early-phase study tests a new drug called BL-M08D1 in 22 adults with blood cancers (lymphoid malignancies) that have returned or not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. Participants must be 18-75 years old and have a life expectancy of at least 3 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY LYMPHOID MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Harbin Medical University Cancer Hospital
RECRUITINGHarbin, Heilongjiang, China
Contact
Conditions
Explore the condition pages connected to this study.